logo

Ovid Therapeutics Inc. (OVID)



Trade OVID now with
  Date
  Headline
3/3/2021 7:05:33 AM Takeda Gets Global Rights At Closing From Ovid For Soticlestat For Dravet Syndrome, Lennox-Gastaut Syndrome
8/25/2020 7:06:11 AM Takeda Pharma: Phase 2 ELEKTRA Study Of Soticlestat Meets Primary Endpoint
7/13/2020 9:04:02 AM Ovid And Angelini To Develop, Manufacture And Commercialize OV101 For Treatment Of Angelman Syndrome In Europe
7/13/2020 7:06:35 AM Ovid Therapeutics, Angelini Pharma Enter Exclusive License Agreement To Develop OV101
6/19/2020 8:05:15 AM Ovid Therapeutics Secures FDA Rare Pediatric Disease Designation For OV101
5/7/2020 7:47:36 AM Ovid Says OV101 Met Study's Primary Objective Of Safety And Tolerability
11/18/2019 4:08:55 PM Ovid Therapeutics Appoints Jason Tardio As Chief Commercial Officer
10/4/2019 8:34:40 AM Ovid Therapeutics Prices $32.5 Mln Of Securities In Concurrent Public Offerings Of Common Stock And Preferred Stock